Another retrospective study on 73 advanced NSCLC patients receiving anti-PD−1/PD-L1 monotherapy confirmed these results: Higher TGR at first evaluation was correlated with inferior outcomes (higher TGR vs. lower HR 2.74, 95% CI 1.34–5.61, p = 0.006). This evidence concerns the gene CD274 and non-small cell lung carcinoma.